Abbott Seeks Psoriasis Indication For Humira
This article was originally published in The Pink Sheet Daily
Executive Summary
The TNF inhibitor would join J&J’s Remicade and Wyeth’s Enbrel with an indication for the treatment of chronic plaque psoriasis.
You may also be interested in...
Abbott’s Humira Gets FDA Nod For Adult Plaque Psoriasis
A crowded market for Humira’s fifth indication fails to intimidate Abbott, which envisions the drug as a “formidable competitor” in chronic adult plaque psoriasis, firm tells “The Pink Sheet” DAILY.
Abbott’s Humira Gets FDA Nod For Adult Plaque Psoriasis
A crowded market for Humira’s fifth indication fails to intimidate Abbott, which envisions the drug as a “formidable competitor” in chronic adult plaque psoriasis, firm tells “The Pink Sheet” DAILY.
Abbott Submits Humira sBLA for Juvenile Rheumatoid Arthritis
If approved, Humira would compete directly with Wyeth/Amgen’s Enbrel in the indication.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: